

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Emerging therapies in rheumatoid arthritis: focus... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1549/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1549" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies" />
    
            <meta name="og:title" content="F1000Research Article: Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies.">
            <meta name="og:description" content="Read the latest article version by Ladislav Senolt, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="20463">
            <meta name="article-id" content="18688">
            <meta name="dc.title" content="Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies">
            <meta name="dc.description" content="Advances in the treatment of rheumatoid arthritis (RA) are attributed to several aspects such as new classification criteria enabling early diagnosis and intensive treatment with the application of treat-to-target principles as well as better understanding of the pathogenesis of RA contributing to the development of targeted therapies. However, reaching remission is still not achieved in most patients with RA, which is one of the driving forces behind the continuous development of novel therapies and the optimization of therapeutic strategies. This review will outline several new therapeutic antibodies modulating anti-inflammatory cytokines interleukin (IL)-2 and IL-10 and pro-inflammatory mediators granulocyte-macrophage colony-stimulating factor, fractalkine, and IL-6 that are in various stages of clinical development as well as the progress in manufacturing biotechnologies contributing to the next generation of antibodies and their potential to expand the therapeutic armamentarium for RA. In addition, the fate of unsuccessful therapies including agents targeting IL-15, the IL-20 family, IL-21, chemokine CXCL10, B-cell activating factor (BAFF), and regulatory T (Treg) cells or a novel concept targeting synovial fibroblasts via cadherin-11 will be discussed.">
            <meta name="dc.subject" content="rheumatoid arthritis, biological therapies, monoclonal antibodies, therapeutic strategies">
            <meta name="dc.creator" content="Senolt, Ladislav">
            <meta name="dc.date" content="2019/08/30">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.18688.1">
            <meta name="dc.source" content="F1000Research 2019 8:1549">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="rheumatoid arthritis">
            <meta name="prism.keyword" content="biological therapies">
            <meta name="prism.keyword" content="monoclonal antibodies">
            <meta name="prism.keyword" content="therapeutic strategies">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/08/30">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1549">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.18688.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1549">
            <meta name="citation_title" content="Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies">
            <meta name="citation_abstract" content="Advances in the treatment of rheumatoid arthritis (RA) are attributed to several aspects such as new classification criteria enabling early diagnosis and intensive treatment with the application of treat-to-target principles as well as better understanding of the pathogenesis of RA contributing to the development of targeted therapies. However, reaching remission is still not achieved in most patients with RA, which is one of the driving forces behind the continuous development of novel therapies and the optimization of therapeutic strategies. This review will outline several new therapeutic antibodies modulating anti-inflammatory cytokines interleukin (IL)-2 and IL-10 and pro-inflammatory mediators granulocyte-macrophage colony-stimulating factor, fractalkine, and IL-6 that are in various stages of clinical development as well as the progress in manufacturing biotechnologies contributing to the next generation of antibodies and their potential to expand the therapeutic armamentarium for RA. In addition, the fate of unsuccessful therapies including agents targeting IL-15, the IL-20 family, IL-21, chemokine CXCL10, B-cell activating factor (BAFF), and regulatory T (Treg) cells or a novel concept targeting synovial fibroblasts via cadherin-11 will be discussed.">
            <meta name="citation_description" content="Advances in the treatment of rheumatoid arthritis (RA) are attributed to several aspects such as new classification criteria enabling early diagnosis and intensive treatment with the application of treat-to-target principles as well as better understanding of the pathogenesis of RA contributing to the development of targeted therapies. However, reaching remission is still not achieved in most patients with RA, which is one of the driving forces behind the continuous development of novel therapies and the optimization of therapeutic strategies. This review will outline several new therapeutic antibodies modulating anti-inflammatory cytokines interleukin (IL)-2 and IL-10 and pro-inflammatory mediators granulocyte-macrophage colony-stimulating factor, fractalkine, and IL-6 that are in various stages of clinical development as well as the progress in manufacturing biotechnologies contributing to the next generation of antibodies and their potential to expand the therapeutic armamentarium for RA. In addition, the fate of unsuccessful therapies including agents targeting IL-15, the IL-20 family, IL-21, chemokine CXCL10, B-cell activating factor (BAFF), and regulatory T (Treg) cells or a novel concept targeting synovial fibroblasts via cadherin-11 will be discussed.">
            <meta name="citation_keywords" content="rheumatoid arthritis, biological therapies, monoclonal antibodies, therapeutic strategies">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Ladislav Senolt">
            <meta name="citation_author_institution" content="Department of Rheumatology, First Faculty of Medicine, Charles University, Institute of Rheumatology, Prague, Czech Republic, 128 50, Czech Republic">
            <meta name="citation_publication_date" content="2019/08/30">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1549">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.18688.1">
            <meta name="citation_firstpage" content="1549">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1549/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1549.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=20463 /> <input type=hidden id=articleId name=articleId value=18688 /> <input type=hidden id=xmlUrl value="/articles/8-1549/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1549-v1.xml"> <input type=hidden id=article_uuid value=663a0acd-774b-4012-b9b6-0a32fd3a2a5c /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.18688.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.18688.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1549"
  },
  "headline": "Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies",
  "datePublished": "2019-08-30T15:50:17",
  "dateModified": "2019-08-30T15:50:17",
  "author": [
    {
      "@type": "Person",
      "name": "Ladislav Senolt"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Advances in the treatment of rheumatoid arthritis (RA) are attributed to several aspects such as new classification criteria enabling early diagnosis and intensive treatment with the application of treat-to-target principles as well as better understanding of the pathogenesis of RA contributing to the development of targeted therapies. However, reaching remission is still not achieved in most patients with RA, which is one of the driving forces behind the continuous development of novel therapies and the optimization of therapeutic strategies. This review will outline several new therapeutic antibodies modulating anti-inflammatory cytokines interleukin (IL)-2 and IL-10 and pro-inflammatory mediators granulocyte-macrophage colony-stimulating factor, fractalkine, and IL-6 that are in various stages of clinical development as well as the progress in manufacturing biotechnologies contributing to the next generation of antibodies and their potential to expand the therapeutic armamentarium for RA. In addition, the fate of unsuccessful therapies including agents targeting IL-15, the IL-20 family, IL-21, chemokine CXCL10, B-cell activating factor (BAFF), and regulatory T (Treg) cells or a novel concept targeting synovial fibroblasts via cadherin-11 will be discussed."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1549",
            "name": "Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=20463 data-id=18688 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18688.1" data-recommended="" data-doi="10.12688/f1000research.18688.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1549/v1/pdf?article_uuid=663a0acd-774b-4012-b9b6-0a32fd3a2a5c" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-18688-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-18688-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-18688-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Senolt L. Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1549 (<a class=new-orange href="https://doi.org/10.12688/f1000research.18688.1" target=_blank>https://doi.org/10.12688/f1000research.18688.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-18688-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=18688 id=track-article-signin-18688 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18688?target=/articles/8-1549">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20463 /> <input name=articleId type=hidden value=18688 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:seno@revma.cz" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Ladislav Senolt</span></a><a href="https://orcid.org/0000-0001-5500-7312" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-5500-7312</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:seno@revma.cz" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Ladislav Senolt</span></a><a href="http://orcid.org/0000-0001-5500-7312" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-5500-7312</div></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 30 Aug 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.18688.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Rheumatology, First Faculty of Medicine, Charles University, Institute of Rheumatology, Prague, Czech Republic, 128 50, Czech Republic<br/> <p> <div class=margin-bottom> Ladislav Senolt <br/> <span>Roles: </span> Conceptualization, Resources, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=55239-52249></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=16082-52248></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Advances in the treatment of rheumatoid arthritis (RA) are attributed to several aspects such as new classification criteria enabling early diagnosis and intensive treatment with the application of treat-to-target principles as well as better understanding of the pathogenesis of RA contributing to the development of targeted therapies. However, reaching remission is still not achieved in most patients with RA, which is one of the driving forces behind the continuous development of novel therapies and the optimization of therapeutic strategies. This review will outline several new therapeutic antibodies modulating anti-inflammatory cytokines interleukin (IL)-2 and IL-10 and pro-inflammatory mediators granulocyte-macrophage colony-stimulating factor, fractalkine, and IL-6 that are in various stages of clinical development as well as the progress in manufacturing biotechnologies contributing to the next generation of antibodies and their potential to expand the therapeutic armamentarium for RA. In addition, the fate of unsuccessful therapies including agents targeting IL-15, the IL-20 family, IL-21, chemokine CXCL10, B-cell activating factor (BAFF), and regulatory T (Treg) cells or a novel concept targeting synovial fibroblasts via cadherin-11 will be discussed. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> rheumatoid arthritis, biological therapies, monoclonal antibodies, therapeutic strategies </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Ladislav Senolt (<a href="mailto:seno@revma.cz">seno@revma.cz</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Ladislav Senolt </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Ladislav Senolt has been involved in clinical trials or had lectures related to the following companies: AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly, Merck Sharp and Dohme, Mylan, Novartis, Pfizer, Roche, Takeda and UCB. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was supported by the Project for Conceptual Development for the institution of Ministry of Health Czech Republic - Institute of Rheumatology (number 023728). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2019 Senolt L. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Senolt L. Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1549 (<a href="https://doi.org/10.12688/f1000research.18688.1" target=_blank>https://doi.org/10.12688/f1000research.18688.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 30 Aug 2019, <b>8</b>(F1000 Faculty Rev):1549 (<a href="https://doi.org/10.12688/f1000research.18688.1" target=_blank>https://doi.org/10.12688/f1000research.18688.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 30 Aug 2019, <b>8</b>(F1000 Faculty Rev):1549 (<a href="https://doi.org/10.12688/f1000research.18688.1" target=_blank>https://doi.org/10.12688/f1000research.18688.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d17221e125>Introduction</h2><p class="" id=d17221e128>In recent years, dramatic advances have emerged across medical disciplines in understanding the pathogenesis of immune-mediated inflammatory diseases, which are accompanied by a significant shift in treatment options<sup><a href="#ref-1">1</a></sup>. One of the most significant advances has been shown in the treatment of rheumatoid arthritis (RA), in which the discovery of glucocorticoid activity was among the first therapeutic milestones in the 1950s<sup><a href="#ref-2">2</a></sup>, followed by widespread use of methotrexate since the turn of the 1980s and 1990s<sup><a href="#ref-3">3</a></sup>. Later on, success in the treatment of RA can be attributed to the introduction of new classification criteria allowing earlier diagnosis and treatment and application of the treat-to-target principles with the aim to induce remission or at least low disease activity<sup><a href="#ref-4">4</a><a href="#ref-6">6</a></sup>. The biggest breakthrough in the treatment of RA, however, comes with biologic therapy, which has gradually begun to spread since the beginning of the new millennium with the introduction of tumor necrosis factor (TNF) inhibitors into clinical practice<sup><a href="#ref-7">7</a></sup>.</p><p class="" id=d17221e154>Targeted disease-modifying antirheumatic drugs (DMARDs), consisting of biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs), antagonize soluble cytokines and their receptors and directly affect immune cell activity or intracellular signaling pathways<sup><a href="#ref-8">8</a><a href="#ref-10">10</a></sup>. The effect of targeted therapies is relatively rapid and often accompanied by a significant suppression of inflammation. In most cases, it can substantially improve quality of life and stop or significantly slow the progression of functional and structural impairment<sup><a href="#ref-11">11</a></sup>. Currently, out of the biological therapies, five original TNF inhibitors and already even more biosimilar TNF inhibitors, two interleukin-6 receptor (IL-6R) inhibitors, and one IL-1 receptor inhibitor as well as B-lymphocyte (CD20) and co-stimulatory signal (CD28-B7 interaction) for T-cell activation inhibitors are available for the treatment of RA (<a href="#T1">Table 1</a>). In addition to bDMARDs, two tsDMARDs, including Janus kinase inhibitors (JAKi) tofacitinib (pan-JAKi) and baricitinib (JAK1/2i) (<a href="#T1">Table 1</a>), have expanded the treatment armamentarium<sup><a href="#ref-12">12</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Currently approved targeted therapies for rheumatoid arthritis</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d17221e189 class=n-a></a><thead><a name=d17221e191 class=n-a></a><tr><a name=d17221e193 class=n-a></a><th align=left colspan=2 rowspan=1><a name=d17221e195 class=n-a></a>Original biologic DMARDs</th><th align=left colspan=1 rowspan=1><a name=d17221e198 class=n-a></a>Target </th><th align=left colspan=2 rowspan=1><a name=d17221e201 class=n-a></a>Structure</th></tr></thead><tbody><a name=d17221e206 class=n-a></a><tr><a name=d17221e208 class=n-a></a><td align=left colspan=2 rowspan=1><a name=d17221e210 class=n-a></a>Infliximab (35 mg i.v. every 8 weeks)</td><td align=left colspan=1 rowspan=1><a name=d17221e213 class=n-a></a>TNF</td><td align=left colspan=2 rowspan=1><a name=d17221e216 class=n-a></a>Chimeric mAb</td></tr><tr><a name=d17221e220 class=n-a></a><td align=left colspan=2 rowspan=1><a name=d17221e222 class=n-a></a>Adalimumab (40 mg s.c. every other week)</td><td align=left colspan=1 rowspan=1><a name=d17221e225 class=n-a></a>TNF</td><td align=left colspan=2 rowspan=1><a name=d17221e228 class=n-a></a>Human mAb</td></tr><tr><a name=d17221e232 class=n-a></a><td align=left colspan=2 rowspan=1><a name=d17221e234 class=n-a></a>Etanercept (50 mg s.c. every week)</td><td align=left colspan=1 rowspan=1><a name=d17221e237 class=n-a></a>TNF</td><td align=left colspan=2 rowspan=1><a name=d17221e240 class=n-a></a>Fc fusion protein</td></tr><tr><a name=d17221e244 class=n-a></a><td align=left colspan=2 rowspan=1><a name=d17221e246 class=n-a></a>Golimumab (50 mg s.c. once a month)</td><td align=left colspan=1 rowspan=1><a name=d17221e249 class=n-a></a>TNF</td><td align=left colspan=2 rowspan=1><a name=d17221e252 class=n-a></a>Human mAb</td></tr><tr><a name=d17221e256 class=n-a></a><td align=left colspan=2 rowspan=1><a name=d17221e258 class=n-a></a>Certolizumab pegol (200 mg s.c. every other week)</td><td align=left colspan=1 rowspan=1><a name=d17221e261 class=n-a></a>TNF</td><td align=left colspan=2 rowspan=1><a name=d17221e264 class=n-a></a>Humanized PEGylated Fab fragment</td></tr><tr><a name=d17221e269 class=n-a></a><td align=left colspan=2 rowspan=1><a name=d17221e271 class=n-a></a>Rituximab (1,000 mg i.v. every 6 months)</td><td align=left colspan=1 rowspan=1><a name=d17221e274 class=n-a></a>CD20 (B-cells)</td><td align=left colspan=2 rowspan=1><a name=d17221e277 class=n-a></a>Chimeric mAb</td></tr><tr><a name=d17221e281 class=n-a></a><td align=left colspan=2 rowspan=1><a name=d17221e283 class=n-a></a>Abatacept (125 mg s.c. every week)</td><td align=left colspan=1 rowspan=1><a name=d17221e286 class=n-a></a>CD80/86 (costimulation)</td><td align=left colspan=2 rowspan=1><a name=d17221e289 class=n-a></a>Fc fusion protein</td></tr><tr><a name=d17221e293 class=n-a></a><td align=left colspan=2 rowspan=1><a name=d17221e295 class=n-a></a>Tocilizumab (162 mg s.c. every week)</td><td align=left colspan=1 rowspan=1><a name=d17221e298 class=n-a></a>IL-6R</td><td align=left colspan=2 rowspan=1><a name=d17221e301 class=n-a></a>Humanized mAb</td></tr><tr><a name=d17221e305 class=n-a></a><td align=left colspan=2 rowspan=1><a name=d17221e307 class=n-a></a>Sarilumab (150200 mg s.c. every other week)</td><td align=left colspan=1 rowspan=1><a name=d17221e310 class=n-a></a>IL-6R</td><td align=left colspan=2 rowspan=1><a name=d17221e313 class=n-a></a>Human mAb</td></tr><tr><a name=d17221e317 class=n-a></a><td align=left colspan=2 rowspan=1><a name=d17221e319 class=n-a></a><b>Targeted synthetic DMARDs</b></td><td align=left colspan=1 rowspan=1><a name=d17221e323 class=n-a></a><b>Target</b></td><td align=left colspan=2 rowspan=1><a name=d17221e327 class=n-a></a><b>Structure</b></td></tr><tr><a name=d17221e332 class=n-a></a><td align=left colspan=2 rowspan=1><a name=d17221e334 class=n-a></a>Tofacitinib (10 mg daily)</td><td align=left colspan=1 rowspan=1><a name=d17221e337 class=n-a></a>JAK1, JAK2, JAK3</td><td align=left colspan=2 rowspan=1><a name=d17221e340 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Small molecule</td></tr><tr><a name=d17221e345 class=n-a></a><td align=left colspan=2 rowspan=1><a name=d17221e347 class=n-a></a>Baricitinib (24 mg daily)</td><td align=left colspan=1 rowspan=1><a name=d17221e350 class=n-a></a>JAK1, JAK2</td><td align=left colspan=2 rowspan=1><a name=d17221e353 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Small molecule</td></tr><tr><a name=d17221e357 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e359 class=n-a></a><b>Biosimilar DMARDs</b></td><td align=left colspan=1 rowspan=1><a name=d17221e363 class=n-a></a><b>Target</b></td><td align=left colspan=1 rowspan=1><a name=d17221e367 class=n-a></a><b>Reference product</b></td><td align=left colspan=1 rowspan=1><a name=d17221e371 class=n-a></a><b>Approved by EMA/FDA</b></td><td align=left colspan=1 rowspan=1><a name=d17221e375 class=n-a></a><b>Manufacturer</b></td></tr><tr><a name=d17221e380 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e382 class=n-a></a>Remsima/Inflectra (CT-P13)</td><td align=left colspan=1 rowspan=1><a name=d17221e385 class=n-a></a>TNF</td><td align=left colspan=1 rowspan=1><a name=d17221e388 class=n-a></a>Infliximab</td><td align=left colspan=1 rowspan=1><a name=d17221e391 class=n-a></a>2013/2016</td><td align=left colspan=1 rowspan=1><a name=d17221e394 class=n-a></a>Celltrion</td></tr><tr><a name=d17221e398 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e400 class=n-a></a>Flixabi/Renflexis (SB2)</td><td align=left colspan=1 rowspan=1><a name=d17221e403 class=n-a></a>TNF</td><td align=left colspan=1 rowspan=1><a name=d17221e406 class=n-a></a>Infliximab</td><td align=left colspan=1 rowspan=1><a name=d17221e409 class=n-a></a>2016/2017</td><td align=left colspan=1 rowspan=1><a name=d17221e412 class=n-a></a>Samsung Bioepis/Biogen</td></tr><tr><a name=d17221e416 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e418 class=n-a></a>Zessly/Ifixi (GP1111/PF-06438179)</td><td align=left colspan=1 rowspan=1><a name=d17221e421 class=n-a></a>TNF</td><td align=left colspan=1 rowspan=1><a name=d17221e424 class=n-a></a>Infliximab</td><td align=left colspan=1 rowspan=1><a name=d17221e427 class=n-a></a>2018/2017</td><td align=left colspan=1 rowspan=1><a name=d17221e430 class=n-a></a>Sandoz (EU)/Pfizer (US)</td></tr><tr><a name=d17221e434 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e436 class=n-a></a>Amgevita/Amjevita (ABP 501)</td><td align=left colspan=1 rowspan=1><a name=d17221e439 class=n-a></a>TNF</td><td align=left colspan=1 rowspan=1><a name=d17221e442 class=n-a></a>Adalimumab</td><td align=left colspan=1 rowspan=1><a name=d17221e445 class=n-a></a>2017/2016</td><td align=left colspan=1 rowspan=1><a name=d17221e448 class=n-a></a>Amgen</td></tr><tr><a name=d17221e453 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e455 class=n-a></a>Cyltezo (BI 695501)</td><td align=left colspan=1 rowspan=1><a name=d17221e458 class=n-a></a>TNF</td><td align=left colspan=1 rowspan=1><a name=d17221e461 class=n-a></a>Adalimumab</td><td align=left colspan=1 rowspan=1><a name=d17221e464 class=n-a></a>2017/2017</td><td align=left colspan=1 rowspan=1><a name=d17221e467 class=n-a></a>Boehringer Ingelheim</td></tr><tr><a name=d17221e471 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e473 class=n-a></a>Imraldi (SB5)</td><td align=left colspan=1 rowspan=1><a name=d17221e476 class=n-a></a>TNF</td><td align=left colspan=1 rowspan=1><a name=d17221e479 class=n-a></a>Adalimumab</td><td align=left colspan=1 rowspan=1><a name=d17221e482 class=n-a></a>2017/<a href="#TFN1">*</a></td><td align=left colspan=1 rowspan=1><a name=d17221e487 class=n-a></a>Samsung Bioepis/Biogen</td></tr><tr><a name=d17221e491 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e493 class=n-a></a>Hyrimoz (GP2017)</td><td align=left colspan=1 rowspan=1><a name=d17221e496 class=n-a></a>TNF</td><td align=left colspan=1 rowspan=1><a name=d17221e499 class=n-a></a>Adalimumab</td><td align=left colspan=1 rowspan=1><a name=d17221e502 class=n-a></a>2018/2018</td><td align=left colspan=1 rowspan=1><a name=d17221e505 class=n-a></a>Sandoz</td></tr><tr><a name=d17221e509 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e511 class=n-a></a>Hulio (MYL-1401A)</td><td align=left colspan=1 rowspan=1><a name=d17221e514 class=n-a></a>TNF</td><td align=left colspan=1 rowspan=1><a name=d17221e517 class=n-a></a>Adalimumab</td><td align=left colspan=1 rowspan=1><a name=d17221e520 class=n-a></a>2018/2018</td><td align=left colspan=1 rowspan=1><a name=d17221e523 class=n-a></a>Mylan</td></tr><tr><a name=d17221e527 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e529 class=n-a></a>Benepali (SB4)</td><td align=left colspan=1 rowspan=1><a name=d17221e532 class=n-a></a>TNF</td><td align=left colspan=1 rowspan=1><a name=d17221e535 class=n-a></a>Etanercept</td><td align=left colspan=1 rowspan=1><a name=d17221e538 class=n-a></a>2016/<a href="#TFN1">*</a></td><td align=left colspan=1 rowspan=1><a name=d17221e543 class=n-a></a>Samsung Bioepis/Biogen</td></tr><tr><a name=d17221e547 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e549 class=n-a></a>Erelzi (GP2015)</td><td align=left colspan=1 rowspan=1><a name=d17221e552 class=n-a></a>TNF</td><td align=left colspan=1 rowspan=1><a name=d17221e555 class=n-a></a>Etanercept</td><td align=left colspan=1 rowspan=1><a name=d17221e558 class=n-a></a>2017/2016</td><td align=left colspan=1 rowspan=1><a name=d17221e561 class=n-a></a>Sandoz</td></tr><tr><a name=d17221e566 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e568 class=n-a></a>Truxima (CT P10)</td><td align=left colspan=1 rowspan=1><a name=d17221e571 class=n-a></a>CD20</td><td align=left colspan=1 rowspan=1><a name=d17221e574 class=n-a></a>Rituximab</td><td align=left colspan=1 rowspan=1><a name=d17221e577 class=n-a></a>2017/2018</td><td align=left colspan=1 rowspan=1><a name=d17221e580 class=n-a></a>Celltrion/Hospira (Pfizer)</td></tr><tr><a name=d17221e584 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e586 class=n-a></a>Rixathon</td><td align=left colspan=1 rowspan=1><a name=d17221e589 class=n-a></a>CD20</td><td align=left colspan=1 rowspan=1><a name=d17221e592 class=n-a></a>Rituximab</td><td align=left colspan=1 rowspan=1><a name=d17221e595 class=n-a></a>2017</td><td align=left colspan=1 rowspan=1><a name=d17221e598 class=n-a></a>Sandoz (EU)</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d17221e606 class=n-a></a><p id=d17221e608> CD, cluster of differentiation; DMARDs, disease-modifying antirheumatic drugs; EMA, European Medicines Agency; FDA, US Food and Drug Administration; IL, interleukin; IL-6R, interleukin-6 receptor; i.v., intravenously; JAK, Janus kinase; mAb, monoclonal antibody; s.c., subcutaneously; TNF, tumor necrosis factor</p><p id=TFN1>*accepted for review by FDA, assessed 19 March 2019.</p></div></div></div><p class="" id=d17221e617>Although the fate of patients with RA has improved significantly and a milder course of disease can be observed than in the past<sup><a href="#ref-13">13</a></sup>, persistent remission, let alone drug-free remission or complete cure, is still elusive<sup><a href="#ref-14">14</a></sup>. This review will outline several new directions for the potential new therapeutic antibodies and treatment strategies for RA, new biological drugs against new targets, and biological drugs against already-known targets that are currently in early or late stages of clinical development.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17221e631>Cytokine and cell-targeted therapies</h2><p class="" id=d17221e634>The development of biological therapies for RA has been facilitated by two main assumptions. The first prerequisite is an increasing understanding of the pathophysiological processes in which systemic immune mediators, immune cells, and signaling pathways play a role and have become targets for specific immune interventions<sup><a href="#ref-15">15</a></sup>. The second important assumption is the dynamic development of the pharmaceutical industry and advances in genetic engineering and biotechnology<sup><a href="#ref-16">16</a></sup>. Potential therapeutic antibodies that are in various stages of clinical development are summarized in <a href="#f1">Figure 1</a>.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/20463/a41c3418-3f2e-4fa3-a1dd-dcec7d1340f4_figure1.gif"><img alt="a41c3418-3f2e-4fa3-a1dd-dcec7d1340f4_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/20463/a41c3418-3f2e-4fa3-a1dd-dcec7d1340f4_figure1.gif"></a><div class=caption><h3>Figure 1. Potential biological therapies for the management of rheumatoid arthritis that are currently in various stages of clinical development.</h3><p id=d17221e658>Black text shows therapies that were effective in the treatment of rheumatoid arthritis, although some of the drugs are not further evaluated in rheumatoid arthritis owing to company prioritization. White text shows therapies that failed to prove efficacy or whose clinical trials were terminated owing to safety concerns.</p><p id=d17221e661>*However, anti-CD20 monoclonal antibody such as rituximab is effective and licensed for the treatment of rheumatoid arthritis.</p><p id=d17221e664>BAFF, B-cell activating factor; CXCL, C-X-C motif ligand; GM-CSF, granulocyte-macrophage colony-stimulating factor; GM-CSFR, granulocyte-macrophage colony-stimulating factor receptor; IL, interleukin; mAb, monoclonal antibody; TNF, tumor necrosis factor; Treg, T regulatory</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17221e674>New targets in later phases of development</h2><div class=section><a name=d17221e677 class=n-a></a><h3 class=section-title>Granulocyte-macrophage colony-stimulating factor</h3><p class="" id=d17221e682>Granulocyte-macrophage colony-stimulating factor (GM-CSF) was first described in the 1970s and is considered a pro-inflammatory cytokine, which is upregulated upon stimulation with multiple mediators such as lipopolysaccharide (LPS) or TNF and is produced by a variety of immune as well as resident tissue cells<sup><a href="#ref-17">17</a></sup>. As the expression of GM-CSF is increased in the synovial tissue and synovial fluid of patients with RA, it can stimulate the synthesis of adhesion molecules and pro-inflammatory cytokines, and it can also activate synovial fibroblasts and polarize macrophages into an inflammatory M1 phenotype, thus promoting rheumatoid synovial inflammation<sup><a href="#ref-18">18</a></sup>. At present, several monoclonal antibodies targeting the GM-CSF pathway in patients with RA are being studied<sup><a href="#ref-19">19</a></sup>.</p><p class="" id=d17221e697>Mavrilimumab (CAM-3001), a monoclonal antibody against GM-CSF receptor alpha being developed by MedImmune, has been extensively evaluated in the EARTH development program<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup>. Mavrilimumab was administered in a phase II dose-ranging study (10100 mg) every other week for a total of 12 weeks to patients with active RA on background methotrexate<sup><a href="#ref-20">20</a></sup>. The primary endpoint was met: the greater proportion of patients receiving mavrilimumab compared with placebo achieved a 1.2 decrease in disease activity score (DAS28-CRP) from baseline at week 12 (55.7% versus 34.7%; <i>p</i>=0.003). The 100 mg dose demonstrated a significant effect versus placebo on DAS28-CRP &lt;2.6 (23.1% versus 6.7%, <i>p</i>=0.016). In a phase IIb study in RA patients with inadequate response to at least one conventional synthetic DMARD (csDMARD), significantly more mavrilimumab-treated (150, 100, and 30 mg) patients achieved American College of Rheumatology definition of improvement (ACR20) compared with placebo at week 24 (73.4%, 61.2%, 50.6% versus 24.7%, respectively [<i>p</i>&lt;0.001]) and clinically meaningful response was observed as early as one week after treatment initiation<sup><a href="#ref-21">21</a></sup>. Another phase IIb study evaluated the efficacy and safety of mavrilimumab and golimumab (anti-TNF) in patients with RA who have had an inadequate response to csDMARDs and anti-TNF agents<sup><a href="#ref-22">22</a></sup>. Mavrilimumab demonstrated numerically lower response rates compared with golimumab in patients with inadequate response to csDMARDs and similar efficacy to that of golimumab in the anti-TNF non-responders. However, the study was not powered to provide a direct comparison between mavrilimumab and golimumab, and it is probable that a suboptimal dosage of mavrilimumab was used (100 mg every other week)<sup><a href="#ref-22">22</a></sup>. Pulmonary safety assessments were performed because the inhibition of GM-CSF signaling has the potential to affect the clearance of surfactant by alveolar macrophages and thus be responsible for pulmonary alveolar proteinosis. Although there was a potential risk of this rare disease, including neutropenia, infections, and other lung toxicities associated with the blockade of GM-CSF, none of these studies nor a long-term extension study up to 3.3 years revealed such concerns<sup><a href="#ref-23">23</a></sup>. Mavrilimumab demonstrated sustained efficacy and an acceptable safety profile; however, due to future clinical development plans, the study was terminated (ClinicalTrials.gov Identifier: NCT01712399).</p><p class="" id=d17221e737>Otilimab (GSK 3196165 or MOR103) is a fully human high-affinity IgG monoclonal antibody against GM-CSF being developed by GlaxoSmithKline. In a phase IIb dose-ranging study (BAROQUE), patients with active RA were randomized to placebo or otilimab (22.5, 45, 90, 135, or 180 mg) administered weekly for five injections, and then every other week until week 50<sup><a href="#ref-24">24</a></sup>. Dose-related treatment effect with the onset of clinical response as early as week one was observed for all doses. However, the primary endpoint (DAS28 remission at week 24) was not achieved; it was only numerically higher in patients at the highest dose of otilimab versus placebo (16% versus 3%; <i>p</i>=0.134). In addition, exposure to otilimab was lower than predicted owing to increased apparent clearance. In July 2019, a phase III clinical program (ContRAst) was announced, in which otilimab (90 and 150 mg weekly doses) will be compared with two treatments with different modes of action: JAKi (tofacitinib) and anti-IL-6R (sarilumab) (https://www.gsk.com).</p><p class="" id=d17221e747>Namilumab (MT203), lenzilumab (KB003), and gimsilumab (MORAb-022) being developed by Takeda, KaloBios Pharmaceuticals, and Morphotek, respectively, are fully human IgG1 monoclonal antibodies against GM-CSF. While initial studies, at least with namilumab<sup><a href="#ref-25">25</a></sup>, demonstrated good safety and promising efficacy data, no further results from phase II studies have been reported so far<sup><a href="#ref-19">19</a></sup>. In addition, based on negative results from a psoriasis study<sup><a href="#ref-26">26</a></sup> and results from a proof-of-concept study in RA (ClinicalTrials.gov Identifier: NCT02393378), further studies on namilumab in psoriasis and RA were terminated.</p><p class="" id=d17221e763>Interestingly, GM-CSF-targeting therapies are also being studied in other rheumatic diseases. For instance, otilimab was studied in patients with hand osteoarthritis and showed numerical reduction in pain and functional impairment, while little difference was observed with placebo on tender and swollen joints, including magnetic resonance imaging (MRI) endpoints<sup><a href="#ref-27">27</a></sup>. In patients with axial spondyloarthritis, a phase IIa proof-of-concept study evaluating the safety and efficacy of namilumab has been recruiting subjects since August 2018 (ClinicalTrials.gov Identifier: NCT03622658).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17221e774>Old targets with the focus on interleukin-6</h2><p class="" id=d17221e777>In mid-2017, sarilumab (trade name Kevzara), a human monoclonal antibody against IL-6R, was approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of RA. Sarilumab showed significantly greater affinity to recombinant human IL-6R compared with tocilizumab and longer half-life with a similar safety profile<sup><a href="#ref-28">28</a>,<a href="#ref-29">29</a></sup>. Further biological drugs targeting IL-6 pathways are in development.</p><p class="" id=d17221e787>Clazakizumab (formerly ALD518 and BMS-945429) is a humanized monoclonal antibody against IL-6. In a phase IIb study<sup><a href="#ref-30">30</a></sup>, the primary endpoint was met; ACR20 response rates at week 12 were greater for clazakizumab (25, 100, and 200 mg) once monthly in combination with methotrexate (MTX) or clazakizumab monotherapy (100 and 200 mg) versus MTX (76.3%, 73.3% and 60.0% or 55.0% and 61.0% versus 39.3%; <i>p</i>&lt;0.05). Also, remission rates as assessed by DAS28-CRP for clazakizumab plus MTX were greater than for MTX plus original adalimumab (40.049.2% versus 23.7%). The treatment was well tolerated with no unanticipated safety signals, consistent with the known pharmacologic effects of IL-6 blockade. Bristol-Myers Squibb has decided, based on portfolio prioritization, to return worldwide rights to clazakizumab to Alder BioPharmaceuticals. However, no further trials in RA are ongoing. The drug is currently in the early phases of development for the treatment of kidney transplant recipients with late antibody-mediated rejection (ClinicalTrials.gov Identifier: NCT03380377 and NCT03380962).</p><p class="" id=d17221e797>Olokizumab (CDP6038), a humanized monoclonal antibody against IL-6, was formerly developed by UCB Pharma and out-licensed to R-Pharm in 2013. In a phase IIb study, the primary endpoint was met; patients with active RA who had previously failed TNF inhibitor therapy demonstrated a significant decrease in DAS28-CRP at week 12 for all doses (60 mg, 120 mg, and 240 mg) administrated every four or every two weeks with results comparable to tocilizumab<sup><a href="#ref-31">31</a></sup>. Safety data were consistent with the use of IL-6-targeted therapy. Although no further results have been reported, phase III studies (CREDO) are either completed (ClinicalTrials.gov Identifier: NCT02760368, NCT02760433) or ongoing (ClinicalTrials.gov Identifier: NCT02760407, NCT03120949).</p><p class="" id=d17221e804>Sirukumab (CNTO-136; proposed trade name Plivensia), a human monoclonal antibody against IL-6, was developed by Centocor, GlaxoSmithKline, and Janssen Biotech. Sirukumab was investigated at doses of 100 mg and 50 mg every two and four weeks, respectively, in five phase III trials (SIRROUND) in a broad spectrum of patients with RA<sup><a href="#ref-32">32</a></sup>. Sirukumab showed significant improvements in disease activity, physical function, and quality of life along with inhibition of radiographic progression<sup><a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup>. In a head-to-head study with adalimumab, sirukumab monotherapy showed greater improvements in disease activity (DAS28) but similar ACR50 response rates at week 24<sup><a href="#ref-35">35</a></sup>. Although the long-term safety of sirukumab seems to be similar to that of other IL-6-inhibiting agents, drug regulatory authorities suggested re-evaluating the safety profile of sirukumab for increased mortality rates in post open-label studies<sup><a href="#ref-32">32</a></sup>. Interestingly, the drug is currently under development for the treatment of major depressive disorder (ClinicalTrials.gov Identifier: NCT02473289).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17221e829>New targets in early phases of development</h2><div class=section><a name=d17221e832 class=n-a></a><h3 class=section-title>Interleukin-2</h3><p class="" id=d17221e837>IL-2, first cloned in the early 1980s, is predominantly produced by CD4<sup>+</sup> T-cells and activated dendritic cells and has pleiotropic functions (for review, see <a href="#ref-36">36</a>). In high doses, IL-2 has been found to promote effector T cells, whereas low-dose IL-2 (ld-IL2) activates regulatory T cells (Tregs) and thus can have a broad therapeutic potential in many autoimmune and inflammatory diseases. Indeed, the results of a first prospective, phase IIIa clinical trial recently demonstrated that ld-IL2 (1,000,000 IU/day) given for five days and then once every other week for six months selectively activated and expanded Tregs without activating effector T cells. Furthermore, the authors reported signals of efficacy without safety issues in 46 patients across 11 autoimmune and inflammatory chronic diseases, including RA, ankylosing spondylitis, systemic lupus erythematosus (SLE), and psoriasis<sup><a href="#ref-37">37</a></sup>. In addition, <i>in vitro</i> and first-in-human data on a fusion protein of IL-2 mutein and human Fc (AMG 592) demonstrated dose-dependent, selective expansion of Tregs with no increase of major pro-inflammatory cytokines such as IL-6, TNF, or interferon- (IFN-) in healthy volunteers<sup><a href="#ref-38">38</a></sup>. Based on these data, another phase Ib/IIa study evaluating the safety and efficacy of AMG 592 has been underway in patients with RA since May 2018 (ClinicalTrials.gov Identifier: NCT03410056) but also in patients with SLE (ClinicalTrials.gov Identifier: NCT03451422).</p></div><div class=section><a name=d17221e858 class=n-a></a><h3 class=section-title>Interleukin-10</h3><p class="" id=d17221e863>IL-10 is produced by virtually all leukocytes and inhibits the production of pro-inflammatory cytokines, e.g. TNF and IFN-, and abrogates antigen presentation and cell proliferation (for review, see <a href="#ref-39">39</a>). Despite the fact that it belongs to the most potent anti-inflammatory cytokine, limited efficacy with subcutaneously administered recombinant IL-10 was observed in a phase I trial in patients with RA in the past<sup><a href="#ref-40">40</a></sup>.</p><p class="" id=d17221e873>Several reasons for this discrepancy can be speculated, e.g. complex mechanism of pathophysiological action of IL-10, including potential pro-inflammatory activity<sup><a href="#ref-41">41</a></sup>, or short half-life of IL-10 hampering effective delivery of recombinant IL-10 to the sites of inflammation. To overcome these obstacles, Dekavil (F8IL10), a fully human anti-inflammatory immunocytokine composed of the vascular-targeting anti-fibronectin domain fused to IL-10, is under investigation in patients with RA<sup><a href="#ref-42">42</a></sup>. In a phase II clinical trial, Dekavil (30600 mg/kg) is administered once a week for eight consecutive weeks by subcutaneous injection in combination with MTX to RA patients who have previously failed at least one TNF inhibitor. Preliminary data have demonstrated some signs of efficacy, with 46% demonstrating ACR20 clinical response after eight weeks of drug administration. Dekavil was well tolerated; however, mild injection site reaction occurred in 60% of the patients<sup><a href="#ref-43">43</a></sup>.</p></div><div class=section><a name=d17221e889 class=n-a></a><h3 class=section-title>Fractalkine</h3><p class="" id=d17221e894>Fractalkine (FKN) is known as a CX3C chemokine that promotes cell adhesion and chemotaxis, but also angiogenesis and osteoclastogenesis, and increases the production of inflammatory mediators, thus playing a significant role in the pathogenesis of RA (reviewed in <a href="#ref-44">44</a>). Recently, first data from a phase II, multicenter, randomized, double-blind, placebo-controlled study with anti-FKN monoclonal antibody (E6011) in patients with active RA were released<sup><a href="#ref-45">45</a></sup>. This novel approach targeting FKN demonstrated reliable safety and promising efficacy with a dose-dependent clinical response, particularly in patients who showed higher baseline CD16<sup>+</sup> monocytes (ACR20 at week 24: 30% for placebo, 46.7% for 100 mg, 57.7% for 200 mg, and 69.6% for 400/200 mg).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17221e912>Unsuccessful biological therapies in rheumatoid arthritis</h2><p class="" id=d17221e915>Although several pro-inflammatory cytokines play a significant role in the pathogenesis of RA and their inhibition contributed to a significant reduction in synovial inflammation and joint damage in an experimental model of arthritis and proved to be effective in early phases of development in humans, further studies failed to confirm significant efficacy<sup><a href="#ref-46">46</a></sup> (<a href="#T2">Table 2</a>). For instance, IL-1 inhibitors are approved but only modestly effective in RA while highly effective in several autoinflammatory diseases<sup><a href="#ref-47">47</a></sup>. An early phase study with IL-15 inhibitor therapy seemed to be efficient<sup><a href="#ref-48">48</a></sup>, but a phase II clinical trial of a fully human monoclonal antibody against IL-15 failed to confirm significant efficacy (ClinicalTrials.gov Identifier: NCT00433875). Although targeting the IL-23/17 axis is effective in spondyloarthritis<sup><a href="#ref-49">49</a></sup>, strategies to block the IL-17 pathway, IL-12/23 p40, or IL-23 did not prove to be effective in patients with established RA, and the clinical research programs in RA were discontinued<sup><a href="#ref-50">50</a></sup>. Similarly, the IL-20 family of cytokines such as IL-20 and IL-22 play a significant role in the process of immune cell activation and bone destruction, and although an early phase trial with the IL-20 inhibitor fletikumab was well tolerated and effective, particularly in patients with seropositive RA, further studies with fletikumab and also IL-22 inhibitor fezakinumab were completed several years ago with negative or no final results released<sup><a href="#ref-51">51</a>,<a href="#ref-52">52</a></sup>. Although IL-21 plays an important role in the activation of the immune system, an early phase first-in-man trial with an IL-21 inhibitor (NNC0114-0000-0005) in patients with RA and healthy subjects was finished in 2012 and no further results have been released (ClinicalTrials.gov Identifier: NCT01208506). The first study demonstrating good safety and clinical efficacy of a chemokine inhibitor in patients with RA evaluated eldelumab (MDX-1100), a fully human anti-CXCL10 (anti-IP-10) monoclonal antibody<sup><a href="#ref-53">53</a></sup>; however, no further data were released.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Selected unsuccessful biological therapies in rheumatoid arthritis</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d17221e964 class=n-a></a><thead><a name=d17221e966 class=n-a></a><tr><a name=d17221e968 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d17221e970 class=n-a></a>Drug</th><th align=left colspan=1 rowspan=1><a name=d17221e973 class=n-a></a>Target</th><th align=left colspan=1 rowspan=1><a name=d17221e976 class=n-a></a>Reason for failure</th><th align=left colspan=1 rowspan=1><a name=d17221e979 class=n-a></a>Citation</th></tr></thead><tbody><a name=d17221e984 class=n-a></a><tr><a name=d17221e986 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e988 class=n-a></a>HuMax-IL15 (anti-IL-15 mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e991 class=n-a></a>IL-15</td><td align=left colspan=1 rowspan=1><a name=d17221e994 class=n-a></a>Lack of efficacy</td><td align=center colspan=1 rowspan=1><a name=d17221e997 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#TFN2">*</a></td></tr><tr><a name=d17221e1003 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1005 class=n-a></a>Brodalumab (anti-IL-17R mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1008 class=n-a></a>IL-17</td><td align=left colspan=1 rowspan=1><a name=d17221e1011 class=n-a></a>Lack of efficacy</td><td align=right colspan=1 rowspan=1><a name=d17221e1014 class=n-a></a>50</td></tr><tr><a name=d17221e1018 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1020 class=n-a></a>Secukinumab (anti-IL-17A mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1023 class=n-a></a>IL-17</td><td align=left colspan=1 rowspan=1><a name=d17221e1026 class=n-a></a>Lack of efficacy</td><td align=right colspan=1 rowspan=1><a name=d17221e1029 class=n-a></a>50</td></tr><tr><a name=d17221e1033 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1035 class=n-a></a>Ixekizumab (anti-IL-17A mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1038 class=n-a></a>IL-17</td><td align=left colspan=1 rowspan=1><a name=d17221e1041 class=n-a></a>Lack of efficacy</td><td align=right colspan=1 rowspan=1><a name=d17221e1044 class=n-a></a>50</td></tr><tr><a name=d17221e1048 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1050 class=n-a></a>Bimekizumab (dual anti-IL-17A/F mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1053 class=n-a></a>IL-17</td><td align=left colspan=1 rowspan=1><a name=d17221e1056 class=n-a></a>Lack of efficacy</td><td align=right colspan=1 rowspan=1><a name=d17221e1059 class=n-a></a>50</td></tr><tr><a name=d17221e1064 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1066 class=n-a></a>Ustekinumab (anti-IL-12/23p40mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1069 class=n-a></a>IL-12/IL-23</td><td align=left colspan=1 rowspan=1><a name=d17221e1072 class=n-a></a>Lack of efficacy</td><td align=right colspan=1 rowspan=1><a name=d17221e1075 class=n-a></a>50</td></tr><tr><a name=d17221e1079 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1081 class=n-a></a>Guselkumab (anti-IL-23 mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1084 class=n-a></a>IL-23</td><td align=left colspan=1 rowspan=1><a name=d17221e1087 class=n-a></a>Lack of efficacy</td><td align=right colspan=1 rowspan=1><a name=d17221e1090 class=n-a></a>50</td></tr><tr><a name=d17221e1094 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1096 class=n-a></a>Remtolumab (dual anti-TNF/IL-17A)</td><td align=left colspan=1 rowspan=1><a name=d17221e1099 class=n-a></a>TNF/IL-17</td><td align=left colspan=1 rowspan=1><a name=d17221e1102 class=n-a></a>Not higher efficacy than adalimumab</td><td align=right colspan=1 rowspan=1><a name=d17221e1105 class=n-a></a>67</td></tr><tr><a name=d17221e1109 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1111 class=n-a></a>NNC0114 (anti-IL-21 mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1114 class=n-a></a>IL-21</td><td align=left colspan=1 rowspan=1><a name=d17221e1117 class=n-a></a>No final results released</td><td align=right colspan=1 rowspan=1><a name=d17221e1120 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#TFN3">+</a></td></tr><tr><a name=d17221e1126 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1128 class=n-a></a>Fletikumab (anti-IL-20 mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1131 class=n-a></a>IL-20</td><td align=left colspan=1 rowspan=1><a name=d17221e1134 class=n-a></a>Lack of efficacy</td><td align=right colspan=1 rowspan=1><a name=d17221e1137 class=n-a></a>51</td></tr><tr><a name=d17221e1141 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1143 class=n-a></a>Fezakinumab (anti-IL-22 mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1146 class=n-a></a>IL-22</td><td align=left colspan=1 rowspan=1><a name=d17221e1149 class=n-a></a>Negative or no final results released</td><td align=right colspan=1 rowspan=1><a name=d17221e1152 class=n-a></a>51</td></tr><tr><a name=d17221e1157 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1159 class=n-a></a>Eldelumab (anti-CXCL10 mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1162 class=n-a></a>CXCL10</td><td align=left colspan=1 rowspan=1><a name=d17221e1165 class=n-a></a>Effective/safe, but no final results released</td><td align=right colspan=1 rowspan=1><a name=d17221e1168 class=n-a></a>53</td></tr><tr><a name=d17221e1172 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1174 class=n-a></a>Mavrilimumab (anti-GM-CSFR)</td><td align=left colspan=1 rowspan=1><a name=d17221e1177 class=n-a></a>GM-CSFR</td><td align=left colspan=1 rowspan=1><a name=d17221e1180 class=n-a></a>Effective/safe, terminated (sponsor decision)</td><td align=right colspan=1 rowspan=1><a name=d17221e1183 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#TFN4"></a></td></tr><tr><a name=d17221e1189 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1191 class=n-a></a>Namilumab (anti-GM-CSF)</td><td align=left colspan=1 rowspan=1><a name=d17221e1194 class=n-a></a>GM-CSF</td><td align=left colspan=1 rowspan=1><a name=d17221e1197 class=n-a></a>Lack of efficacy</td><td align=right colspan=1 rowspan=1><a name=d17221e1200 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#TFN5"></a></td></tr><tr><a name=d17221e1206 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1208 class=n-a></a>Tabalumab (anti-BAFF)</td><td align=left colspan=1 rowspan=1><a name=d17221e1211 class=n-a></a>BAFF</td><td align=left colspan=1 rowspan=1><a name=d17221e1214 class=n-a></a>Lack of efficacy</td><td align=right colspan=1 rowspan=1><a name=d17221e1217 class=n-a></a>56</td></tr><tr><a name=d17221e1221 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1223 class=n-a></a>Belimumab (anti-BAFF)</td><td align=left colspan=1 rowspan=1><a name=d17221e1226 class=n-a></a>BAFF</td><td align=left colspan=1 rowspan=1><a name=d17221e1229 class=n-a></a>Terminated (sponsor decision)</td><td align=right colspan=1 rowspan=1><a name=d17221e1232 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#TFN6"></a></td></tr><tr><a name=d17221e1238 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1240 class=n-a></a>Ocrelizumab (anti-CD20 mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1243 class=n-a></a>B-cells</td><td align=left colspan=1 rowspan=1><a name=d17221e1246 class=n-a></a>Risk/benefit consideration</td><td align=right colspan=1 rowspan=1><a name=d17221e1249 class=n-a></a>54</td></tr><tr><a name=d17221e1254 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1256 class=n-a></a>Ofatumumab (anti-CD20 mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1259 class=n-a></a>B-cells</td><td align=left colspan=1 rowspan=1><a name=d17221e1262 class=n-a></a>Risk/benefit consideration</td><td align=right colspan=1 rowspan=1><a name=d17221e1265 class=n-a></a>54</td></tr><tr><a name=d17221e1269 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1271 class=n-a></a>SBI-087 (CD20-targeted SMIP)</td><td align=left colspan=1 rowspan=1><a name=d17221e1274 class=n-a></a>B-cells</td><td align=left colspan=1 rowspan=1><a name=d17221e1277 class=n-a></a>Further development terminated</td><td align=right colspan=1 rowspan=1><a name=d17221e1280 class=n-a></a>55</td></tr><tr><a name=d17221e1284 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1286 class=n-a></a>Alemtuzumab (anti-CD52 mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1289 class=n-a></a>T-cells</td><td align=left colspan=1 rowspan=1><a name=d17221e1292 class=n-a></a>Safety</td><td align=right colspan=1 rowspan=1><a name=d17221e1295 class=n-a></a>57</td></tr><tr><a name=d17221e1299 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1301 class=n-a></a>Keliximab (anti-CD4 mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1304 class=n-a></a>T-cells</td><td align=left colspan=1 rowspan=1><a name=d17221e1307 class=n-a></a>Safety</td><td align=right colspan=1 rowspan=1><a name=d17221e1310 class=n-a></a>57</td></tr><tr><a name=d17221e1314 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1316 class=n-a></a>Clenoliximab (anti-CD4 mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1319 class=n-a></a>T-cells</td><td align=left colspan=1 rowspan=1><a name=d17221e1322 class=n-a></a>Safety</td><td align=right colspan=1 rowspan=1><a name=d17221e1325 class=n-a></a>57</td></tr><tr><a name=d17221e1329 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1331 class=n-a></a>Tregalizumab (anti-CD4 mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1334 class=n-a></a>Treg cells</td><td align=left colspan=1 rowspan=1><a name=d17221e1337 class=n-a></a>Lack of efficacy</td><td align=right colspan=1 rowspan=1><a name=d17221e1340 class=n-a></a>58</td></tr><tr><a name=d17221e1345 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d17221e1347 class=n-a></a>RG6125 (anti-cadherin-11 mAb)</td><td align=left colspan=1 rowspan=1><a name=d17221e1350 class=n-a></a>Cadherin-11</td><td align=left colspan=1 rowspan=1><a name=d17221e1353 class=n-a></a>Lack of efficacy</td><td align=right colspan=1 rowspan=1><a name=d17221e1356 class=n-a></a>59</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d17221e1364 class=n-a></a><p id=d17221e1366> BAFF, B-cell activating factor; CXCL, chemokine C-X-C motif ligand; GM-CSFR, granulocyte-macrophage colony-stimulating factor receptor ; IL, interleukin; mAb, monoclonal antibody; SMIP, Small Modular ImmunoPharmaceutical; TNF, tumor necrosis factor; Treg, T regulatory</p><p id=TFN2>* ClinicalTrials.gov Identifier: NCT00433875</p><p id=TFN3>+ ClinicalTrials.gov Identifier: NCT01208506</p><p id=TFN4> ClinicalTrials.gov Identifier: NCT01712399</p><p id=TFN5> ClinicalTrials.gov Identifier: NCT03622658</p><p id=TFN6> ClinicalTrials.gov Identifier: NCT00583557</p></div></div></div><p class="" id=d17221e1388>Several strategies to inhibit B-cells were tested; for instance, humanized and human monoclonal antibodies ocrelizumab (trade name Ocrevus) and ofatumumab (trade name Arzerra) proved to be effective in patients with RA. However, after risk/benefit consideration, further studies were discontinued<sup><a href="#ref-54">54</a></sup>. In order to reduce the molecule, promote penetration to sites of inflammation, and improve efficacy, single-chain antibody polypeptides known as SMIPs (small modular immunopharmaceuticals) have been developed that are approximately one-half to one-third of the size of the standard monoclonal antibody. A next-generation, humanized SMIP protein therapeutic against the CD20 antigen (SBI-087) was evaluated in patients with RA, but further development was terminated<sup><a href="#ref-55">55</a></sup>. In addition, a further strategy to inhibit B-cell differentiation and survival via anti-B-cell activating factor (anti-BAFF) antibody has also failed in the treatment of patients with RA<sup><a href="#ref-56">56</a></sup>. Direct T-cell-targeting therapies such as alemtuzumab, keliximab, and clenoliximab did not show satisfactory results and were accompanied by a number of serious adverse reactions associated with severe CD4<sup>+</sup> T-lymphopenia and rash<sup><a href="#ref-57">57</a></sup>. Tregalizumab (BT-061) is a humanized agonist antibody that selectively activates Treg lymphocytes and was tested as an innovative treatment for RA; however, it also did not show significant clinical benefit<sup><a href="#ref-58">58</a></sup>.</p><p class="" id=d17221e1415>Recently, a novel approach targeting synovial fibroblasts in RA via the inhibition of cadherin-11 was presented<sup><a href="#ref-59">59</a></sup>. Although an interesting concept, anti-cadherin-11 (RG6125) given on top of anti-TNF therapy in patients with active RA failed to be more effective than placebo and the study was discontinued<sup><a href="#ref-59">59</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17221e1429>Next-generation antibodies</h2><p class="" id=d17221e1432>Conventional monoclonal antibodies (e.g. infliximab or adalimumab), Fc fusion proteins (etanercept and abatacept), and one antibody-derived molecule, a PEGylated anti-TNF Fab fragment (certolizumab pegol), are widely used for the treatment of patients with RA. Further advances in antibody engineering have led to the development of so-called next-generation therapeutic antibodies representing antibody fragments, dual/bispecific targeting variants, and immunocytokines<sup><a href="#ref-60">60</a><a href="#ref-62">62</a></sup>. The purpose is to develop antibodies that are smaller, more stable, have higher affinity and improved tissue penetration, and have lower immunogenicity and toxicity than conventional antibodies. For instance, nanobodies are single-domain antibodies that were originally developed after the discovery of camelid antibodies consisting of heavy chain variable domain (lacking the Fc-equivalent region) and can be engineered to bind to two (or even more) different antigens or epitopes on the cell surface, so-called bispecific (even multispecific) antibodies<sup><a href="#ref-61">61</a>,<a href="#ref-62">62</a></sup>. These antibodies are frequently used to treat cancer. Another therapeutic success was achieved by the development of immunocytokines, a fusion of an antibody and cytokine, which are widely studied as an anticancer therapy<sup><a href="#ref-63">63</a></sup> and should extend cytokine half-life, reduce systemic adverse events, and deliver the cytokine specifically to sites of inflammation as mentioned above (Dekavil or AMG 592).</p><p class="" id=d17221e1453>Belgian biopharmaceutical company Ablynx has developed unique new-generation bispecific therapeutic nanobodies ozoralizumab (ATN-103) and vobarilizumab (ALX0061) for the treatment of RA, the first humanized bispecific nanobodies, which neutralize TNF and IL-6R, respectively, and also bind to human serum albumin to increase the half-life. Ozoralizumab was tested in subcutaneous form at a once-monthly dosing interval in patients with RA and after 12 weeks of treatment, EULAR response was obtained in 97% of patients, an ACR20 response was achieved in 84%, and DAS28 remission was seen in 38% of patients with RA<sup><a href="#ref-64">64</a></sup>. A phase II study evaluating long-term safety and tolerability was completed in 2012 (ClinicalTrials.gov identifier: NCT01063803), and no further reports of development have been made so far. An early phase study with vobarilizumab demonstrated promising results as well, with ACR20 response rates of up to 84% and DAS28 remission rates of up to 58%<sup><a href="#ref-65">65</a></sup>. In addition, in a phase IIb monotherapy study (head-to-head versus tocilizumab) in RA patients<sup><a href="#ref-66">66</a></sup>, a similar proportion of vobarilizumab-treated patients achieved ACR20 response at week 12 compared with tocilizumab (7381% versus 78%). Although more patients achieved DAS remission on highest vobarilizumab dose (225 mg every other week), when using more stringent CDAI and SDAI remission criteria, a similar efficacy was obtained in the monotherapy with vobarilizumab (510%) and tocilizumab groups (911%).</p><p class="" id=d17221e1468>Remtolumab (ABT-122), developed by AbbVie, is another bispecific antibody, a full-length IgG with dual-variable domains (DVD-Ig), targeting two important human cytokines: TNF and IL-17A. Based on a TNF-transgenic mouse model of arthritis, dual inhibition of both cytokines proved to be more effective in suppressing inflammation and bone/cartilage destruction than either cytokine inhibitor alone<sup><a href="#ref-67">67</a></sup>. However, a phase II trial demonstrated that a strategy of dual inhibition of TNF and IL-17A with remtolumab does not appear to be significantly different from that of TNF inhibition alone with adalimumab in human patients with RA and psoriatic arthritis<sup><a href="#ref-68">68</a></sup>. In addition to this finding, recent data proved that another DVD-Ig lutikizumab (ABT-981) targeting IL-1/ did not improve pain or synovitis in patients with both erosive hand osteoarthritis and knee osteoarthritis<sup><a href="#ref-69">69</a>,<a href="#ref-70">70</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17221e1489>Conclusion</h2><p class="" id=d17221e1492>Biologicals have become an essential part of the therapeutic armamentarium for RA, significantly ameliorating disease activity and improving quality of life. Furthermore, the progress in our understanding of the pathogenesis of RA has significantly contributed to the development of novel intracellular targeted therapies such as JAK inhibitors tofacitinib and baricitinib that have already been implemented in routine clinical practice. Nowadays, more selective JAK inhibitors and other targeted synthetic therapies are in various stages of clinical development in RA, which is beyond the scope of this review and is reported elsewhere<sup><a href="#ref-71">71</a>,<a href="#ref-72">72</a></sup>. In addition to the development of new therapies, the patent protection of older original biological agents expires and biosimilars have been entering the market within the last few years, thus lowering the price and enabling the treatment of more patients<sup><a href="#ref-73">73</a></sup>.</p><p class="" id=d17221e1506>Despite current practice, early and intensive management with the treat-to-target approach, reaching remission is still not achieved in most patients, which is one of the driving forces behind the continuous development of novel therapies and the optimization of therapeutic strategies<sup><a href="#ref-74">74</a></sup>. Thus, advances in antibody engineering and further therapeutic targets such as neuro-immune modulation, gene therapy, and epigenetic modification are being evaluated in the treatment of RA<sup><a href="#ref-75">75</a><a href="#ref-77">77</a></sup>. In addition, the two main treatment strategies can be potentially applied in the future to improve disease outcome, halt further progression, or even cure the disease either 1) by an induction-maintenance regime with biological therapies administered as early as the diagnosis is established<sup><a href="#ref-78">78</a></sup> or 2) even before clinical arthritis becomes apparent<sup><a href="#ref-79">79</a></sup>. Currently, several ongoing proof-of-concept trials are testing whether targeting T-cells or B-cells can induce immunological reset and be used to prevent the onset of RA<sup><a href="#ref-80">80</a></sup>. An advanced study demonstrated that a single infusion of 1,000 mg rituximab significantly delayed the development of arthritis in patients at risk of developing of RA<sup><a href="#ref-81">81</a></sup>. Other treatment approaches for preventive strategies may represent, for instance, the use of tolerogenic dendritic cells<sup><a href="#ref-82">82</a></sup> or targeting the IL-17/23 axis<sup><a href="#ref-83">83</a></sup> in order to block arthritis development in pre-clinical phases of the disease. However, further research is needed to determine which therapeutic agent or strategy would best suit each individual patient.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d17221e1 class=n-a></a><h2 class=main-title id=d17484>Grant information</h2><p>This work was supported by the Project for Conceptual Development for the institution of Ministry of Health Czech Republic - Institute of Rheumatology (number 023728).</p><p><i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i></p></div><div class=back-section><a name=d17221e1549 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d17745>References</h2><div class="section ref-list"><a name=d17221e1549 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d17221e1556 class=n-a></a>Cho JH, Feldman M: Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. <i>Nat Med.</i> 2015; <b>21</b>(7): 7308. <a target=xrefwindow id=d17221e1564 href="http://www.ncbi.nlm.nih.gov/pubmed/26121193">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1567 href="https://doi.org/10.1038/nm.3897">Publisher Full Text </a> | <a target=xrefwindow id=d17221e1570 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5716342">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d17221e1579 class=n-a></a>Hench PS, Kendall EC, Slocumb CH, <i> et al.</i>: The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocortical hormone in arthritis: preliminary report. <i>Ann Rheum Dis.</i> 1949; <b>8</b>(2): 97104. <a target=xrefwindow id=d17221e1590 href="http://www.ncbi.nlm.nih.gov/pubmed/18623812">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1593 href="https://doi.org/10.1136/ard.8.2.97">Publisher Full Text </a> | <a target=xrefwindow id=d17221e1597 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1030685">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d17221e1606 class=n-a></a>Weinblatt ME, Maier AL: Longterm experience with low dose weekly methotrexate in rheumatoid arthritis. <i>J Rheumatol Suppl.</i> 1990; <b>22</b>: 338. <a target=xrefwindow id=d17221e1614 href="http://www.ncbi.nlm.nih.gov/pubmed/2192058">PubMed Abstract </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d17221e1623 class=n-a></a>Aletaha D, Neogi T, Silman AJ, <i> et al.</i>: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Ann Rheum Dis.</i> 2010; <b>69</b>(9): 15808. <a target=xrefwindow id=d17221e1634 href="http://www.ncbi.nlm.nih.gov/pubmed/20699241">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1637 href="https://doi.org/10.1136/ard.2010.138461">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d17221e1646 class=n-a></a>Felson DT, Smolen JS, Wells G, <i> et al.</i>: American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Ann Rheum Dis.</i> 2011; <b>70</b>(3): 40413. <a target=xrefwindow id=d17221e1657 href="http://www.ncbi.nlm.nih.gov/pubmed/21292833">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1660 href="https://doi.org/10.1136/ard.2011.149765">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d17221e1670 class=n-a></a>Smolen JS, Breedveld FC, Burmester GR, <i> et al.</i>: Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Ann Rheum Dis.</i> 2015; <b>75</b>(1): 315. <a target=xrefwindow id=d17221e1681 href="http://www.ncbi.nlm.nih.gov/pubmed/25969430">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1684 href="https://doi.org/10.1136/annrheumdis-2015-207524">Publisher Full Text </a> | <a target=xrefwindow id=d17221e1688 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4717393">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718325307"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e1697 class=n-a></a>Lipsky PE, van der Heijde DM, St Clair EW, <i> et al.</i>: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. <i>N Engl J Med.</i> 2000; <b>343</b>(22): 1594602. <a target=xrefwindow id=d17221e1708 href="http://www.ncbi.nlm.nih.gov/pubmed/11096166">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1711 href="https://doi.org/10.1056/NEJM200011303432202">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718325307">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d17221e1724 class=n-a></a>Senolt L, Vencovsk J, Pavelka K, <i> et al.</i>: Prospective new biological therapies for rheumatoid arthritis. <i>Autoimmun Rev.</i> 2009; <b>9</b>(2): 1027. <a target=xrefwindow id=d17221e1735 href="http://www.ncbi.nlm.nih.gov/pubmed/19328245">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1738 href="https://doi.org/10.1016/j.autrev.2009.03.010">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d17221e1747 class=n-a></a>Buch MH, Emery P: New therapies in the management of rheumatoid arthritis. <i>Curr Opin Rheumatol.</i> 2011; <b>23</b>(3): 24551. <a target=xrefwindow id=d17221e1755 href="http://www.ncbi.nlm.nih.gov/pubmed/21427579">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1758 href="https://doi.org/10.1097/BOR.0b013e3283454124">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d17221e1767 class=n-a></a>Burmester GR, Feist E, Drner T: Emerging cell and cytokine targets in rheumatoid arthritis. <i>Nat Rev Rheumatol.</i> 2014; <b>10</b>(2): 7788. <a target=xrefwindow id=d17221e1775 href="http://www.ncbi.nlm.nih.gov/pubmed/24217582">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1778 href="https://doi.org/10.1038/nrrheum.2013.168">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d17221e1787 class=n-a></a>Stavre Z, Upchurch K, Kay J, <i> et al.</i>: Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis. <i>Curr Rheumatol Rep.</i> 2016; <b>18</b>(12): 72. <a target=xrefwindow id=d17221e1798 href="http://www.ncbi.nlm.nih.gov/pubmed/27812955">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1801 href="https://doi.org/10.1007/s11926-016-0620-x">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732080072"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e1811 class=n-a></a>Schwartz DM, Kanno Y, Villarino A, <i> et al.</i>: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. <i>Nat Rev Drug Discov.</i> 2017; <b>16</b>(12): 84362. <a target=xrefwindow id=d17221e1822 href="http://www.ncbi.nlm.nih.gov/pubmed/29104284">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1825 href="https://doi.org/10.1038/nrd.2017.201">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732080072">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d17221e1838 class=n-a></a>Kievit W, Fransen J, de Waal Malefijt MC, <i> et al.</i>: Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. <i>Rheumatology (Oxford).</i> 2013; <b>52</b>(8): 15008. <a target=xrefwindow id=d17221e1849 href="http://www.ncbi.nlm.nih.gov/pubmed/23657913">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1852 href="https://doi.org/10.1093/rheumatology/ket166">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d17221e1861 class=n-a></a>Aletaha D, Smolen JS: Achieving Clinical Remission for Patients With Rheumatoid Arthritis. <i>JAMA.</i> 2019; <b>321</b>(5): 457458. <a target=xrefwindow id=d17221e1869 href="http://www.ncbi.nlm.nih.gov/pubmed/30721278">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1872 href="https://doi.org/10.1001/jama.2018.21249">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d17221e1881 class=n-a></a>Veale DJ, Orr C, Fearon U: Cellular and molecular perspectives in rheumatoid arthritis. <i>Semin Immunopathol.</i> 2017; <b>39</b>(4): 34354. <a target=xrefwindow id=d17221e1889 href="http://www.ncbi.nlm.nih.gov/pubmed/28508153">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1892 href="https://doi.org/10.1007/s00281-017-0633-1">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d17221e1901 class=n-a></a>Azhar A, Ahmad E, Zia Q, <i> et al.</i>: Recent Updates on Molecular Genetic Engineering Approaches and Applications of Human Therapeutic Proteins. <i>Curr Protein Pept Sci.</i> 2017; <b>18</b>(3): 21732. <a target=xrefwindow id=d17221e1912 href="http://www.ncbi.nlm.nih.gov/pubmed/27587281">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1915 href="https://doi.org/10.2174/1389203717666160901114911">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d17221e1924 class=n-a></a>Burgess AW, Metcalf D: The nature and action of granulocyte-macrophage colony stimulating factors. <i>Blood.</i> 1980; <b>56</b>(6): 94758. <a target=xrefwindow id=d17221e1932 href="http://www.ncbi.nlm.nih.gov/pubmed/7002232">PubMed Abstract </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d17221e1942 class=n-a></a>Zhou D, Huang C, Lin Z, <i> et al.</i>: Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways. <i>Cell Signal.</i> 2014; <b>26</b>(2): 1927. <a target=xrefwindow id=d17221e1953 href="http://www.ncbi.nlm.nih.gov/pubmed/24219909">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1956 href="https://doi.org/10.1016/j.cellsig.2013.11.004">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733070637"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e1965 class=n-a></a>Cook AD, Hamilton JA: Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor- in rheumatoid arthritis: focus on mavrilimumab. <i>Ther Adv Musculoskelet Dis.</i> 2018; <b>10</b>(2): 2938. <a target=xrefwindow id=d17221e1973 href="http://www.ncbi.nlm.nih.gov/pubmed/29387176">PubMed Abstract </a> | <a target=xrefwindow id=d17221e1976 href="https://doi.org/10.1177/1759720X17752036">Publisher Full Text </a> | <a target=xrefwindow id=d17221e1979 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5784476">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733070637">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d17221e1992 class=n-a></a>Burmester GR, Weinblatt ME, McInnes IB, <i> et al.</i>: Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. <i>Ann Rheum Dis.</i> 2013; <b>72</b>(9): 144552. <a target=xrefwindow id=d17221e2003 href="http://www.ncbi.nlm.nih.gov/pubmed/23234647">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2006 href="https://doi.org/10.1136/annrheumdis-2012-202450">Publisher Full Text </a> | <a target=xrefwindow id=d17221e2010 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3756523">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727317664"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2019 class=n-a></a>Burmester GR, McInnes IB, Kremer J, <i> et al.</i>: A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. <i>Ann Rheum Dis.</i> 2017; <b>76</b>(6): 102030. <a target=xrefwindow id=d17221e2030 href="http://www.ncbi.nlm.nih.gov/pubmed/28213566">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2033 href="https://doi.org/10.1136/annrheumdis-2016-210624">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727317664">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731259669"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2046 class=n-a></a>Weinblatt ME, McInnes IB, Kremer JM, <i> et al.</i>: A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. <i>Arthritis Rheumatol.</i> 2018; <b>70</b>(1): 4959. <a target=xrefwindow id=d17221e2057 href="http://www.ncbi.nlm.nih.gov/pubmed/28941039">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2060 href="https://doi.org/10.1002/art.40323">Publisher Full Text </a> | <a target=xrefwindow id=d17221e2064 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5767745">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731259669">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732542701"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2077 class=n-a></a>Burmester GR, McInnes IB, Kremer JM, <i> et al.</i>: Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor  Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis. <i>Arthritis Rheumatol.</i> 2018; <b>70</b>(5): 67989. <a target=xrefwindow id=d17221e2088 href="http://www.ncbi.nlm.nih.gov/pubmed/29361199">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2091 href="https://doi.org/10.1002/art.40420">Publisher Full Text </a> | <a target=xrefwindow id=d17221e2095 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5947536">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732542701">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d17221e2109 class=n-a></a>Buckley C, Simon Campos JA, Yakushin S, <i> et al.</i>: A Phase IIb Dose-ranging Study of Anti-GM-CSF with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate (abstract). <i>Arthritis Rheumatol.</i> 2018; <b>70</b>(suppl 10): abstract number 1938. <a target=xrefwindow id=d17221e2120 href="https://acrabstracts.org/abstract/a-phase-iib-dose-ranging-study-of-anti-gm-csf-with-methotrexate-treatment-in-patients-with-rheumatoid-arthritis-ra-and-an-inadequate-response-to-methotrexate/">Reference Source</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727384392"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2129 class=n-a></a>Huizinga TW, Batalov A, Stoilov R, <i> et al.</i>: Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. <i>Arthritis Res Ther.</i> 2017; <b>19</b>(1): 53. <a target=xrefwindow id=d17221e2140 href="http://www.ncbi.nlm.nih.gov/pubmed/28274253">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2143 href="https://doi.org/10.1186/s13075-017-1267-3">Publisher Full Text </a> | <a target=xrefwindow id=d17221e2147 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5343373">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727384392">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d17221e2160 class=n-a></a>Papp KA, Gooderham M, Jenkins R, <i> et al.</i>: Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody. <i>Br J Dermatol.</i> 2019; <b>180</b>(6): 135260. <a target=xrefwindow id=d17221e2171 href="http://www.ncbi.nlm.nih.gov/pubmed/30207587">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2174 href="https://doi.org/10.1111/bjd.17195">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d17221e2183 class=n-a></a>Schett G, Bainbridge C, Berkowitz M, <i> et al.</i>: A Phase IIb Study of Anti-GM-CSF Antibody GSK3196165 in Subjects with INflammatory Hand Osteoarthritis (abstract). <i>Arthritis Rheumatol.</i> 2018; <b>70</b>(suppl 10): abstract number 1365. <a target=xrefwindow id=d17221e2194 href="https://acrabstracts.org/abstract/a-phase-iia-study-of-anti-gm-csf-antibody-gsk3196165-in-subjects-with-inflammatory-hand-osteoarthritis/">Reference Source</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d17221e2203 class=n-a></a>Rafque A, Martin J, Blome M, <i> et al.</i>: Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human IL-6 receptor (IL-6R) alpha. <i>Ann Rheum Dis.</i> 2013; <b>72 (suppl 3)</b>, abstract number 797. <a target=xrefwindow id=d17221e2214 href="https://doi.org/10.1136/annrheumdis-2013-eular.2360">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736468241"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2223 class=n-a></a>Avci AB, Feist E, Burmester GR: Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference? <i>BioDrugs.</i> 2018; <b>32</b>(6): 53146. <a target=xrefwindow id=d17221e2231 href="http://www.ncbi.nlm.nih.gov/pubmed/30488231">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2234 href="https://doi.org/10.1007/s40259-018-0320-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736468241">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d17221e2248 class=n-a></a>Weinblatt ME, Mease P, Mysler E, <i> et al.</i>: The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. <i>Arthritis Rheumatol.</i> 2015; <b>67</b>(10): 2591600. <a target=xrefwindow id=d17221e2259 href="http://www.ncbi.nlm.nih.gov/pubmed/26138593">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2262 href="https://doi.org/10.1002/art.39249">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d17221e2271 class=n-a></a>Genovese MC, Fleischmann R, Furst D, <i> et al.</i>: Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. <i>Ann Rheum Dis.</i> 2014; <b>73</b>(9): 160715. <a target=xrefwindow id=d17221e2282 href="http://www.ncbi.nlm.nih.gov/pubmed/24641941">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2285 href="https://doi.org/10.1136/annrheumdis-2013-204760">Publisher Full Text </a> | <a target=xrefwindow id=d17221e2289 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4145439">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d17221e2298 class=n-a></a>Bartoli F, Bae S, Cometi L, <i> et al.</i>: Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018. <i>Expert Rev Clin Immunol.</i> 2018; <b>14</b>(7): 53947. <a target=xrefwindow id=d17221e2309 href="http://www.ncbi.nlm.nih.gov/pubmed/29925278">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2312 href="https://doi.org/10.1080/1744666X.2018.1487291">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727328077"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2321 class=n-a></a>Aletaha D, Bingham CO 3rd, Tanaka Y, <i> et al.</i>: Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. <i>Lancet.</i> 2017; <b>389</b>(10075): 120617. <a target=xrefwindow id=d17221e2332 href="http://www.ncbi.nlm.nih.gov/pubmed/28215362">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2335 href="https://doi.org/10.1016/S0140-6736(17)30401-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727328077">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730362851"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2348 class=n-a></a>Takeuchi T, Thorne C, Karpouzas G, <i> et al.</i>: Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. <i>Ann Rheum Dis.</i> 2017; <b>76</b>(12): 20018. <a target=xrefwindow id=d17221e2359 href="http://www.ncbi.nlm.nih.gov/pubmed/28855173">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2362 href="https://doi.org/10.1136/annrheumdis-2017-211328">Publisher Full Text </a> | <a target=xrefwindow id=d17221e2366 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5705845">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730362851">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732763351"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2379 class=n-a></a>Taylor PC, Schiff MH, Wang Q, <i> et al.</i>: Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-nave patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(5): 65866. <a target=xrefwindow id=d17221e2390 href="http://www.ncbi.nlm.nih.gov/pubmed/29483080">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2393 href="https://doi.org/10.1136/annrheumdis-2017-212496">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732763351">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725439655"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2407 class=n-a></a>Klatzmann D, Abbas AK: The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. <i>Nat Rev Immunol.</i> 2015; <b>15</b>(5): 28394. <a target=xrefwindow id=d17221e2415 href="http://www.ncbi.nlm.nih.gov/pubmed/25882245">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2418 href="https://doi.org/10.1038/nri3823">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725439655">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734495992"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2431 class=n-a></a>Rosenzwajg M, Lorenzon R, Cacoub P, <i> et al.</i>: Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. <i>Ann Rheum Dis.</i> 2019; <b>78</b>(2): 20917. <a target=xrefwindow id=d17221e2442 href="http://www.ncbi.nlm.nih.gov/pubmed/30472651">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2445 href="https://doi.org/10.1136/annrheumdis-2018-214229">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734495992">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d17221e2458 class=n-a></a>Tchao N, Gorski KS, Yuraszeck T, <i> et al.</i>: Amg 592 Is an Investigational IL-2 Mutein That Induces Highly Selective Expansion of Regulatory T Cells. <i>Blood.</i> 2017; <b>130</b>(Suppl 1): 696. <a target=xrefwindow id=d17221e2469 href="http://www.bloodjournal.org/content/130/Suppl_1/696?sso-checked=true">Reference Source</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d17221e2478 class=n-a></a>Saxena A, Khosraviani S, Noel S, <i> et al.</i>: Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. <i>Cytokine.</i> 2015; <b>74</b>(1): 2734. <a target=xrefwindow id=d17221e2489 href="http://www.ncbi.nlm.nih.gov/pubmed/25481648">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2492 href="https://doi.org/10.1016/j.cyto.2014.10.031">Publisher Full Text </a> | <a target=xrefwindow id=d17221e2496 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4454631">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d17221e2505 class=n-a></a>Galeazzi M, Bazzichi L, Sebastiani GD, <i> et al.</i>: A phase IB clinical trial with Dekavil (F8-IL10), an immunoregulatory 'armed antibody' for the treatment of rheumatoid arthritis, used in combination wiIh methotrexate. <i>Isr Med Assoc J.</i> 2014; <b>16</b>(10): 666. <a target=xrefwindow id=d17221e2516 href="http://www.ncbi.nlm.nih.gov/pubmed/25438467">PubMed Abstract </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d17221e2525 class=n-a></a>Verma R, Balakrishnan L, Sharma K, <i> et al.</i>: A network map of Interleukin-10 signaling pathway. <i>J Cell Commun Signal.</i> 2016; <b>10</b>(1): 617. <a target=xrefwindow id=d17221e2536 href="http://www.ncbi.nlm.nih.gov/pubmed/26253919">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2539 href="https://doi.org/10.1007/s12079-015-0302-x">Publisher Full Text </a> | <a target=xrefwindow id=d17221e2543 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4850137">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d17221e2553 class=n-a></a>Maini RNPH, Breedveld PC: Hu lL-10 in subjects with active rheumatoid arthritis (I&amp;A): phase I and cytokine response study. Arthritis Rheum; Abstract Supplement of National Scientific Meeting; Washington, 1997; 224.</span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d17221e2562 class=n-a></a>Galeazzi M, Sebastiani G, Voll R, <i> et al.</i>: Dekavil (F8IL10)  update on the results of clinical trials investigating the immunocytokine in patients with rheumatoid arthritis. <i>Ann Rheum Dis</i> 2018; <b>77</b>(2): 603604. <a target=xrefwindow id=d17221e2573 href="https://doi.org/10.1136/annrheumdis-2018-eular.5550">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d17221e2582 class=n-a></a>Nanki T, Imai T, Kawai S: Fractalkine/CX3CL1 in rheumatoid arthritis. <i>Mod Rheumatol.</i> 2017; <b>27</b>(3): 3927. <a target=xrefwindow id=d17221e2590 href="http://www.ncbi.nlm.nih.gov/pubmed/27484962">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2593 href="https://doi.org/10.1080/14397595.2016.1213481">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d17221e2602 class=n-a></a>Tanaka Y, Takeuchi T, Yamanaka H, <i> et al.</i>: OP0223 EFFICACY AND SAFETY OF E6011, AN ANTI-FRACTALKINE MONOCLONAL ANTIBODY, IN MTX-IR PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Ann Rheum Dis.</i> 2019; <b>78</b>(Suppl 2): 188. <a target=xrefwindow id=d17221e2613 href="https://doi.org/10.1136/annrheumdis-2019-eular.1671">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732533319"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2622 class=n-a></a>Ridgley LA, Anderson AE, Pratt AG: What are the dominant cytokines in early rheumatoid arthritis? <i>Curr Opin Rheumatol.</i> 2018; <b>30</b>(2): 20714. <a target=xrefwindow id=d17221e2630 href="http://www.ncbi.nlm.nih.gov/pubmed/29206659">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2633 href="https://doi.org/10.1097/BOR.0000000000000470">Publisher Full Text </a> | <a target=xrefwindow id=d17221e2636 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5805125">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732533319">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d17221e2649 class=n-a></a>Cavalli G, Dinarello CA: Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. <i>Rheumatology (Oxford).</i> 2015; <b>54</b>(12): 213444. <a target=xrefwindow id=d17221e2657 href="http://www.ncbi.nlm.nih.gov/pubmed/26209330">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2660 href="https://doi.org/10.1093/rheumatology/kev269">Publisher Full Text </a> | <a target=xrefwindow id=d17221e2663 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5009422">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d17221e2673 class=n-a></a>Baslund B, Tvede N, Danneskiold-Samsoe B, <i> et al.</i>: Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. <i>Arthritis Rheum.</i> 2005; <b>52</b>(9): 268692. <a target=xrefwindow id=d17221e2684 href="http://www.ncbi.nlm.nih.gov/pubmed/16142748">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2687 href="https://doi.org/10.1002/art.21249">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733464342"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2696 class=n-a></a>Bridgewood C, Watad A, Cuthbert RJ, <i> et al.</i>: Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics. <i>Curr Opin Rheumatol.</i> 2018; <b>30</b>(5): 52632. <a target=xrefwindow id=d17221e2707 href="http://www.ncbi.nlm.nih.gov/pubmed/29889692">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733464342">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727869572"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2720 class=n-a></a>Baker KF, Isaacs JD: Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? <i>Ann Rheum Dis.</i> 2018; <b>77</b>(2): 17587. <a target=xrefwindow id=d17221e2728 href="http://www.ncbi.nlm.nih.gov/pubmed/28765121">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2731 href="https://doi.org/10.1136/annrheumdis-2017-211555">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727869572">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d17221e2744 class=n-a></a>Kragstrup TW, Andersen T, Heftdal LD, <i> et al.</i>: The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis. <i>Front Immunol.</i> 2018; <b>9</b>: 2226. <a target=xrefwindow id=d17221e2755 href="http://www.ncbi.nlm.nih.gov/pubmed/30319661">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2758 href="https://doi.org/10.3389/fimmu.2018.02226">Publisher Full Text </a> | <a target=xrefwindow id=d17221e2762 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6167463">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d17221e2771 class=n-a></a>enolt L, Leszczynski P, Dokoupilov E, <i> et al.</i>: Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial. <i>Arthritis Rheumatol.</i> 2015; <b>67</b>(6): 143848. <a target=xrefwindow id=d17221e2782 href="http://www.ncbi.nlm.nih.gov/pubmed/25707477">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2785 href="https://doi.org/10.1002/art.39083">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d17221e2794 class=n-a></a>Yellin M, Paliienko I, Balanescu A, <i> et al.</i>: A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. <i>Arthritis Rheum.</i> 2012; <b>64</b>(6): 17309. <a target=xrefwindow id=d17221e2805 href="http://www.ncbi.nlm.nih.gov/pubmed/22147649">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2808 href="https://doi.org/10.1002/art.34330">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732130936"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2818 class=n-a></a>Du FH, Mills EA, Mao-Draayer Y: Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. <i>Auto Immun Highlights.</i> 2017; <b>8</b>(1): 12. <a target=xrefwindow id=d17221e2826 href="http://www.ncbi.nlm.nih.gov/pubmed/29143151">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2829 href="https://doi.org/10.1007/s13317-017-0100-y">Publisher Full Text </a> | <a target=xrefwindow id=d17221e2832 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5688039">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732130936">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d17221e2845 class=n-a></a>Damjanov N, Tlustochowicz M, Aelion J, <i> et al.</i>: Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study. <i>J Rheumatol.</i> 2016; <b>43</b>(12): 2094100. <a target=xrefwindow id=d17221e2856 href="http://www.ncbi.nlm.nih.gov/pubmed/27909139">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2859 href="https://doi.org/10.3899/jrheum.160146">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d17221e2868 class=n-a></a>Genovese MC, Fleischmann RM, Greenwald M, <i> et al.</i>: Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. <i>Ann Rheum Dis.</i> 2013; <b>72</b>(9): 14618. <a target=xrefwindow id=d17221e2879 href="http://www.ncbi.nlm.nih.gov/pubmed/23268367">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2882 href="https://doi.org/10.1136/annrheumdis-2012-202775">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d17221e2891 class=n-a></a>Hepburn TW, Totoritis MC, Davis CB: Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis. <i>Rheumatology (Oxford).</i> 2003; <b>42</b>(1): 5461. <a target=xrefwindow id=d17221e2899 href="http://www.ncbi.nlm.nih.gov/pubmed/12509613">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2902 href="https://doi.org/10.1093/rheumatology/keg030">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732523174"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2911 class=n-a></a>van Vollenhoven RF, Keystone EC, Strand V, <i> et al.</i>: Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(4): 4959. <a target=xrefwindow id=d17221e2922 href="http://www.ncbi.nlm.nih.gov/pubmed/29343509">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2925 href="https://doi.org/10.1136/annrheumdis-2017-212478">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732523174">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d17221e2938 class=n-a></a>Finch R, Sostelly A, Sue-Ling K, <i> et al.</i>: OP0224 RESULTS OF A PHASE 2 STUDY OF RG6125, AN ANTI-CADHERIN-11 MONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO ANTI-TNFALPHA THERAPY. <i>Ann Rheum Dis.</i> 2019; <b>78</b>(Suppl 2): 189. <a target=xrefwindow id=d17221e2949 href="https://doi.org/10.1136/annrheumdis-2019-eular.3028">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735181568"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e2959 class=n-a></a>Schmid AS, Neri D: Advances in antibody engineering for rheumatic diseases. <i>Nat Rev Rheumatol.</i> 2019; <b>15</b>(4): 197207. <a target=xrefwindow id=d17221e2967 href="http://www.ncbi.nlm.nih.gov/pubmed/30814691">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2970 href="https://doi.org/10.1038/s41584-019-0188-8">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735181568">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d17221e2983 class=n-a></a>Steeland S, Vandenbroucke RE, Libert C: Nanobodies as therapeutics: big opportunities for small antibodies. <i>Drug Discov Today.</i> 2016; <b>21</b>(7): 1076113. <a target=xrefwindow id=d17221e2991 href="http://www.ncbi.nlm.nih.gov/pubmed/27080147">PubMed Abstract </a> | <a target=xrefwindow id=d17221e2994 href="https://doi.org/10.1016/j.drudis.2016.04.003">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d17221e3003 class=n-a></a>Kontermann R: Dual targeting strategies with bispecific antibodies. <i>MAbs.</i> 2012; <b>4</b>(2): 18297. <a target=xrefwindow id=d17221e3011 href="http://www.ncbi.nlm.nih.gov/pubmed/22453100">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3014 href="https://doi.org/10.4161/mabs.4.2.19000">Publisher Full Text </a> | <a target=xrefwindow id=d17221e3017 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3361654">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735227980"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e3026 class=n-a></a>Neri D: Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity. <i>Cancer Immunol Res.</i> 2019; <b>7</b>(3): 34854. <a target=xrefwindow id=d17221e3034 href="http://www.ncbi.nlm.nih.gov/pubmed/30824549">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3037 href="https://doi.org/10.1158/2326-6066.CIR-18-0622">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735227980">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d17221e3050 class=n-a></a>Fleischmann R, De Bruyn S, Duby C, <i> et al.</i>: A Novel Individualized Treatment Approach in Open-Label Extension Study of Ozoralizumab (ATN-103) in Subjects with Rheumatoid Arthritis On a Background of Methotrexate. Arthritis Rheumatol. ACR meeting, abstract number 1311. 2012. <a target=xrefwindow id=d17221e3055 href="https://acrabstracts.org/abstract/a-novel-individualized-treatment-approach-in-open-label-extension-study-of-ozoralizumab-atn-103-in-subjects-with-rheumatoid-arthritis-on-a-background-of-methotrexate/">Reference Source</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d17221e3064 class=n-a></a>Holz JB, Sargentini-Maier L, de Bruyn S, <i> et al.</i>: OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA. <i>Ann Rheum Dis.</i> 2014; <b>72</b>(Suppl 3): A64.1A64. <a target=xrefwindow id=d17221e3075 href="https://doi.org/10.1136/annrheumdis-2013-eular.248">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d17221e3085 class=n-a></a>Drner T, Weinblatt M, Beneden KV, <i> et al.</i>: FRI0239 Results of a phase 2b study of vobarilizumab, an anti-interleukin-6 receptor nanobody, as monotherapy in patients with moderate to severe rheumatoid arthritis. <i>Ann Rheum Dis.</i> 2017; <b>76</b>(Suppl 2): 575. <a target=xrefwindow id=d17221e3096 href="https://doi.org/10.1136/annrheumdis-2017-eular.3746">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d17221e3105 class=n-a></a>Fischer JA, Hueber AJ, Wilson S, <i> et al.</i>: Combined inhibition of tumor necrosis factor  and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. <i>Arthritis Rheumatol.</i> 2015; <b>67</b>(1): 5162. <a target=xrefwindow id=d17221e3116 href="http://www.ncbi.nlm.nih.gov/pubmed/25303306">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3119 href="https://doi.org/10.1002/art.38896">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734318797"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e3128 class=n-a></a>Khatri A, Klnder B, Peloso PM, <i> et al.</i>: Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis. <i>Rheumatology (Oxford).</i> 2019; <b>58</b>(2): 35260. <a target=xrefwindow id=d17221e3139 href="http://www.ncbi.nlm.nih.gov/pubmed/30376130">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3142 href="https://doi.org/10.1093/rheumatology/key312">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734318797">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734638833"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e3155 class=n-a></a>Kloppenburg M, Peterfy C, Haugen IK, <i> et al.</i>: Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1 and anti-interleukin-1 dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. <i>Ann Rheum Dis.</i> 2019; <b>78</b>(3): 41320. <a target=xrefwindow id=d17221e3166 href="http://www.ncbi.nlm.nih.gov/pubmed/30552176">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3169 href="https://doi.org/10.1136/annrheumdis-2018-213336">Publisher Full Text </a> | <a target=xrefwindow id=d17221e3173 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6390132">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734638833">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734877302"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e3186 class=n-a></a>Fleischmann RM, Bliddal H, Blanco FJ, <i> et al.</i>: A Phase II Trial of Lutikizumab, an Anti-Interleukin-1/ Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. <i>Arthritis Rheumatol.</i> 2019; <b>71</b>(7): 10561069. <a target=xrefwindow id=d17221e3197 href="http://www.ncbi.nlm.nih.gov/pubmed/30653843">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3200 href="https://doi.org/10.1002/art.40840">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734877302">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727887261"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e3213 class=n-a></a>Cheung TT, McInnes IB: Future therapeutic targets in rheumatoid arthritis? <i>Semin Immunopathol.</i> 2017; <b>39</b>(4): 487500. <a target=xrefwindow id=d17221e3221 href="http://www.ncbi.nlm.nih.gov/pubmed/28451787">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3224 href="https://doi.org/10.1007/s00281-017-0623-3">Publisher Full Text </a> | <a target=xrefwindow id=d17221e3227 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5486796">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727887261">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734943478"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e3241 class=n-a></a>Virtanen A, Haikarainen T, Raivola J, <i> et al.</i>: Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. <i>BioDrugs.</i> 2019; <b>33</b>(1): 1532. <a target=xrefwindow id=d17221e3252 href="http://www.ncbi.nlm.nih.gov/pubmed/30701418">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3255 href="https://doi.org/10.1007/s40259-019-00333-w">Publisher Full Text </a> | <a target=xrefwindow id=d17221e3259 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6373396">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734943478">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d17221e3272 class=n-a></a>Drner T, Strand V, Cornes P, <i> et al.</i>: The changing landscape of biosimilars in rheumatology. <i>Ann Rheum Dis.</i> 2016; <b>75</b>(6): 97482. <a target=xrefwindow id=d17221e3283 href="http://www.ncbi.nlm.nih.gov/pubmed/26964144">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3286 href="https://doi.org/10.1136/annrheumdis-2016-209166">Publisher Full Text </a> | <a target=xrefwindow id=d17221e3290 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4893105">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734156934"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e3299 class=n-a></a>Aletaha D, Smolen JS: Diagnosis and Management of Rheumatoid Arthritis: A Review. <i>JAMA.</i> 2018; <b>320</b>(13): 136072. <a target=xrefwindow id=d17221e3307 href="http://www.ncbi.nlm.nih.gov/pubmed/30285183">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3310 href="https://doi.org/10.1001/jama.2018.13103">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734156934">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727743157"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e3323 class=n-a></a>Koopman FA, Maanen MA, Vervoordeldonk MJ, <i> et al.</i>: Balancing the autonomic nervous system to reduce inflammation in rheumatoid arthritis. <i>J Intern Med.</i> 2017; <b>282</b>(1): 6475. <a target=xrefwindow id=d17221e3334 href="http://www.ncbi.nlm.nih.gov/pubmed/28547815">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3337 href="https://doi.org/10.1111/joim.12626">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727743157">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727429022"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e3350 class=n-a></a>Frank-Bertoncelj M, Klein K, Gay S: Interplay between genetic and epigenetic mechanisms in rheumatoid arthritis. <i>Epigenomics.</i> 2017; <b>9</b>(4): 493504. <a target=xrefwindow id=d17221e3358 href="http://www.ncbi.nlm.nih.gov/pubmed/28322583">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3361 href="https://doi.org/10.2217/epi-2016-0142">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727429022">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d17221e3374 class=n-a></a>Filkov M, Jngel A, Gay RE, <i> et al.</i>: MicroRNAs in rheumatoid arthritis: potential role in diagnosis and therapy. <i>BioDrugs.</i> 2012; <b>26</b>(3): 13141. <a target=xrefwindow id=d17221e3385 href="http://www.ncbi.nlm.nih.gov/pubmed/22494429">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3388 href="https://doi.org/10.2165/11631480-000000000-00000">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d17221e3398 class=n-a></a>van Vollenhoven RF, Nagy G, Tak PP: Early start and stop of biologics: has the time come? <i>BMC Med.</i> 2014; <b>12</b>: 25. <a target=xrefwindow id=d17221e3406 href="http://www.ncbi.nlm.nih.gov/pubmed/24502187">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3409 href="https://doi.org/10.1186/1741-7015-12-25">Publisher Full Text </a> | <a target=xrefwindow id=d17221e3412 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3915229">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d17221e3421 class=n-a></a>van Steenbergen HW, da Silva JAP, Huizinga TWJ, <i> et al.</i>: Preventing progression from arthralgia to arthritis: targeting the right patients. <i>Nat Rev Rheumatol.</i> 2018; <b>14</b>(1): 3241. <a target=xrefwindow id=d17221e3432 href="http://www.ncbi.nlm.nih.gov/pubmed/29118439">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3435 href="https://doi.org/10.1038/nrrheum.2017.185">Publisher Full Text </a> | <a target=xrefwindow id=d17221e3439 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6298577">Free Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733424519"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e3448 class=n-a></a>Hilliquin S, Hugues B, Mitrovic S, <i> et al.</i>: Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(8): 10991106. <a target=xrefwindow id=d17221e3459 href="http://www.ncbi.nlm.nih.gov/pubmed/29884751">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3462 href="https://doi.org/10.1136/annrheumdis-2017-212612">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733424519">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734570531"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e3475 class=n-a></a>Gerlag DM, Safy M, Maijer KI, <i> et al.</i>: Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. <i>Ann Rheum Dis.</i> 2019; <b>78</b>(2): 17985. <a target=xrefwindow id=d17221e3486 href="http://www.ncbi.nlm.nih.gov/pubmed/30504445">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3489 href="https://doi.org/10.1136/annrheumdis-2017-212763">Publisher Full Text </a> | <a target=xrefwindow id=d17221e3493 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6352407">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734570531">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727804776"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e3506 class=n-a></a>Pozsgay J, Szekanecz Z, Srmay G: Antigen-specific immunotherapies in rheumatic diseases. <i>Nat Rev Rheumatol.</i> 2017; <b>13</b>(9): 52537. <a target=xrefwindow id=d17221e3514 href="http://www.ncbi.nlm.nih.gov/pubmed/28701761">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3517 href="https://doi.org/10.1038/nrrheum.2017.107">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727804776">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726936953"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17221e3530 class=n-a></a>Pfeifle R, Rothe T, Ipseiz N, <i> et al.</i>: Regulation of autoantibody activity by the IL-23-T<sub>H</sub>17 axis determines the onset of autoimmune disease. <i>Nat Immunol.</i> 2017; <b>18</b>(1): 10413. <a target=xrefwindow id=d17221e3544 href="http://www.ncbi.nlm.nih.gov/pubmed/27820809">PubMed Abstract </a> | <a target=xrefwindow id=d17221e3548 href="https://doi.org/10.1038/ni.3579">Publisher Full Text </a> | <a target=xrefwindow id=d17221e3551 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5164937">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726936953">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Aug 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1549&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1549&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Rheumatology, First Faculty of Medicine, Charles University, Institute of Rheumatology, Prague, Czech Republic, 128 50, Czech Republic<br/> <p> <div class=margin-bottom> Ladislav Senolt <br/> <span>Roles: </span> Conceptualization, Resources, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1549/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 30 Aug 2019, 8:1549 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.18688.1">https://doi.org/10.12688/f1000research.18688.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2019 Senolt L. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=20463 data-id=18688 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18688.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1549/v1/pdf?article_uuid=663a0acd-774b-4012-b9b6-0a32fd3a2a5c" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.18688.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Senolt L. Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1549 (<a href="https://doi.org/10.12688/f1000research.18688.1" target=_blank>https://doi.org/10.12688/f1000research.18688.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=18688 id=mobile-track-article-signin-18688 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18688?target=/articles/8-1549"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20463 /> <input name=articleId type=hidden value=18688 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Diego Kyburz</strong>, Experimental Rheumatology, University Hospital Basel, Switzerland </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>John Isaacs</strong>, Institute of Cellular Medicine, Newcastle University, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Aug 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1549&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1549&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=55239-52249></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=16082-52248></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1549/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>30 Aug 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Diego Kyburz</strong>, Experimental Rheumatology, University Hospital Basel, Switzerland </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>John Isaacs</strong>, Institute of Cellular Medicine, Newcastle University, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1549&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1549/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Emerging therapies in rheumatoid arthritis:...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1549/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1549/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1549/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Senolt L');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1549/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1549",
            templates : {
                twitter : "Emerging therapies in rheumatoid arthritis: focus on monoclonal.... Senolt L, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1549/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/18688/20463")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "20463");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "47568": 0,
                           "52248": 1,
                           "52249": 0,
                           "47564": 0,
                           "47565": 0,
                           "47566": 0,
                           "47567": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "a67c0356-94d6-4bd9-87db-c9cec396b45a";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1549.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1549.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1549.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1549.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1549.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>